Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC.

Dogan, Izzet; Gurbuz, Mustafa; Paksoy, Nail; Ferhatoglu, Ferhat; Vatansever, Sezai; Saip, Pinar; Demirkazik, Ahmet; Aydiner, Adnan

Dogan, Izzet; Gurbuz, Mustafa; Paksoy, Nail; Ferhatoglu, Ferhat; Vatansever, Sezai; Saip, Pinar; Demirkazik, Ahmet; Aydiner, Adnan.

Affiliation

Dogan I; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey.
Gurbuz M; Ankara University Faculty of Medicine, Medical Oncology, Ankara, Turkey.
Paksoy N; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey.
Ferhatoglu F; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey.
Vatansever S; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey.
Saip P; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey.
Demirkazik A; Ankara University Faculty of Medicine, Medical Oncology, Ankara, Turkey.
Aydiner A; Istanbul University Institute of Oncology, Medical Oncology, Istanbul, Turkey.

Medicine (Baltimore) ; 101(34): e30188, 2022 Aug 26.

Article de En | MEDLINE | ID: mdl-36042659

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Tumeurs du poumon Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans / Male Langue: En Journal: Medicine (Baltimore) Année: 2022 Type de document: Article Pays d'affiliation: Turquie Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google